Sugi Predict

Sugi Predict / Compounds / SCHEMBL3663283

SCHEMBL3663283

SCHEMBL3663283

NC(=O)c1ccc(-c2cn3ccccc3n2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CLK1 P49759 1/20 0.66
▸ DYRK1A Q13627 1/20 0.66
▸ RAB9A P51151 12/20 0.64
▸ NPC1 O15118 11/20 0.64
▸ KDM4E B2RXH2 9/20 0.64
▸ GFER P55789 4/20 0.64
▸ POLB P06746 3/20 0.61
▸ SMN1; SMN2 Q16637 7/20 0.60
▸ ALDH1A1 P00352 5/20 0.60
▸ KMT2A Q03164 3/20 0.60
▸ HPGD P15428 3/20 0.60
▸ MEN1 O00255 2/20 0.60
▸ HTT P42858 2/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ L3MBTL1 Q9Y468 1/20 0.60
▸ PTGS1 P23219 1/20 0.60
▸ PTGS2 P35354 1/20 0.60
▸ PARP1 P09874 1/20 0.59
▸ HDAC6 Q9UBN7 1/20 0.58
▸ PKM P14618 4/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13325928 0.88 RAB9A (0.68) CLK1DYRK1ARAB9ANPC1KDM4E
SCHEMBL3440320 0.87 RAB9A (0.66) CLK1DYRK1ARAB9ANPC1KDM4E
SCHEMBL3661290 0.86 CLK1 (0.67) CLK1DYRK1ARAB9ANPC1KDM4E
SCHEMBL2427998 0.85 RAB9A (0.64) CLK1DYRK1ARAB9ANPC1KDM4E
SCHEMBL3441125 0.85 RAB9A (0.66) CLK1DYRK1ARAB9ANPC1KDM4E
SCHEMBL13325909 0.84 RAB9A (0.83) CLK1DYRK1ARAB9ANPC1KDM4E
SCHEMBL13325938 0.82 RAB9A (0.80) CLK1DYRK1ARAB9ANPC1KDM4E
SCHEMBL11824996 0.82 RAB9A (0.60) CLK1DYRK1ARAB9ANPC1KDM4E
SCHEMBL3440250 0.82 NPC1 (0.67) CLK1DYRK1ARAB9ANPC1KDM4E
SCHEMBL10752842 0.82 RAB9A (0.61) CLK1DYRK1ARAB9ANPC1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230406851-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2023-12-21 — — US disclosed
US-20230406851-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2023-12-21 — — US disclosed
EP-3998267-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF Bellus Health Cough Inc. (CA) 2022-05-18 — — EP disclosed
US-20220062290-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2022-03-03 — — US disclosed
US-20220062290-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2022-03-03 — — US disclosed
EP-3381917-B1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF BELLUS HEALTH COUGH INC (CA) 2021-09-08 — — EP disclosed
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2021-07-29 — — US disclosed
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2021-07-29 — — US disclosed
CN-107485612-B Imidazopyridine compounds and uses thereof 尼奥迈德研究所 2021-03-30 — — CN disclosed
CN-107485612-B Imidazopyridine compounds and uses thereof 尼奥迈德研究所 2021-03-30 — — CN disclosed
US-20150361078-A1 Imidazopyridine Compounds and Uses Thereof GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.3) LIMITED (GB) 2015-12-17 — — US disclosed
EP-2951177-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF Neomed Institute (CA) 2015-12-09 — — EP disclosed
EP-2951177-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF Neomed Institute (CA) 2015-12-09 — — EP disclosed
WO-2014117274-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NEOMED INSTITUTE (CA) 2014-08-07 — — WO disclosed
WO-2014117274-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NEOMED INSTITUTE (CA) 2014-08-07 — — WO disclosed
US-8642788-B2 Activators of executioner procaspases 3, 6 and 7 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-02-04 — — US disclosed
EP-2237784-A1 ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 The Regents of the University of California (US) 2010-10-13 — — EP disclosed
WO-2009089508-A1 ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-07-16 — — WO disclosed
US-4716169-A INOTROPIC AGENTS DR. KARL THOMAE GMBH (DE) 1987-12-29 — — US disclosed
EP-0185345-A1 Imidazo derivatives, their preparation and medicines containing them Dr. Karl Thomae GmbH (DE) 1986-06-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230406851-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NISCH, ABL1, PAICS CLK1 2814/4885DYRK1A 1867/4885RAB9A 2952/4885
US-20150361078-A1 Imidazopyridine Compounds and Uses Thereof NISCH, ABL1, PAICS CLK1 2814/4885DYRK1A 1867/4885RAB9A 2952/4885
US-20220062290-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NISCH, ABL1, PAICS CLK1 2814/4885DYRK1A 1867/4885RAB9A 2952/4885
US-20210228588-A1 IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF NISCH, ABL1, PAICS CLK1 2814/4885DYRK1A 1867/4885RAB9A 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.